Nahid Asghari | Maragheh University of Medical Sciences (original) (raw)
Microbiology (Molecular Cell Biology)
less
Uploads
Papers by Nahid Asghari
SPC, Journal of Medicinal and Pharmaceutical Chemistry Research, May 2, 2023
Bone infection (Osteomyelitis) is an inflammation of the bone that usually results in infection. ... more Bone infection (Osteomyelitis) is an inflammation of the bone that usually results in infection. Nowadays, in situ forming systems are investigated for the osteomyelitis treatment. These systems are in the form of viscous liquid, but they become solid or semi-solid and the drug is released slowly after injection into the infection site. The aim of present study was the long-term release of vancomycin using a PLGA system loaded with drug-containing chitosan nanoparticles. The in situ formulations formed in this study were composed of three main components: polymer, water-miscible solvent, and active pharmaceutical ingredient. PLGA 504H polymer and PEG 250DME solvent with a polymer to solvent ratio of 3:1 was used to prepare the in situ forming system. Chitosan nanoparticles were designed using gelation ionic method by designing the experiment of chitosan nanoparticles with encapsulation efficiency of 51% and drug loading of 25%. Then, by adding different ratios of released drug to loaded drug through nanoparticles in the system, their release profile was examined. The results revealed that adding chitosan nanoparticles reduced burst release by 44% and increased the release time. In this system, the drug can be added to the polymer solution in different proportions of the free form and the drug-containing nanoparticle. Furthermore, in this system, it is possible to use the combination of different drugs in free form or loaded in nanoparticles to improve the treatment process in the system. The use of biodegradable polymers eliminates the need for surgery in the use of this medicinal system. Moreover, this system is biocompatible and non-toxic due to the non-use of organic solvent in the preparation of the system and the use of PEG 250 DME solvent.
SPC, Eurasian Chemical Communications (ECC), Jun 6, 2023
This study aimed to PEGylated cationic nano-niosomes formulation containing curcumin (CUR) for dr... more This study aimed to PEGylated cationic nano-niosomes formulation containing curcumin (CUR) for drug delivery to MCF-7 breast cancer cell lines and slow release of encapsulated CUR to reduce drug side effects on other healthy cells and increase drug effect on cancer cells. In this applied/in vitro study, PEGylated cationic nano-niosomes containing curcumin as herbal anticancer drug in MCF-7 cell line were prepared in laboratory through lipid phase mixing, phosphate buffer addition to a lipid thin film, and the production of nano-niosomes by sonication and dialysis process. Curcumin-containing niosomes were produced using the lipid phase by thin film fabrication method and reduced to a nanometer size by sonication. The average diameter (85.4 nm) of drug-carrying nano-niosomes was determined using a nano-sizer. Our results includes acquisition of technical knowledge of fabricating nano-niosomes containing a herbal bioactive ingredient as a nanosystem with the herbal medicine curcumin, proper loading of curcumin (with anticancer effect) at > 95% inside nano-niosomes with a size of < 100 nm to intensify the effectiveness of this medicine in cancer treatment, and preparation of PEGylated cationic nano-niosomes containing a body-compatible herbal bioactive substance with a slow release curve and good stability in terms of size and surface loading after 2 months of production. The produced curcumin-carrying liposomal nano-carrier has a slow-release curve and body biocompatibility that can be used in preparation of drug delivery systems containing similar hydrophobic drugs as an effective approach in treatment of various cancers, and agriculture, as well as in various pharmaceutical, medical, health, and environmental industries.
SPC, Journal of Medicinal and Pharmaceutical Chemistry Research, May 2, 2023
Bone infection (Osteomyelitis) is an inflammation of the bone that usually results in infection. ... more Bone infection (Osteomyelitis) is an inflammation of the bone that usually results in infection. Nowadays, in situ forming systems are investigated for the osteomyelitis treatment. These systems are in the form of viscous liquid, but they become solid or semi-solid and the drug is released slowly after injection into the infection site. The aim of present study was the long-term release of vancomycin using a PLGA system loaded with drug-containing chitosan nanoparticles. The in situ formulations formed in this study were composed of three main components: polymer, water-miscible solvent, and active pharmaceutical ingredient. PLGA 504H polymer and PEG 250DME solvent with a polymer to solvent ratio of 3:1 was used to prepare the in situ forming system. Chitosan nanoparticles were designed using gelation ionic method by designing the experiment of chitosan nanoparticles with encapsulation efficiency of 51% and drug loading of 25%. Then, by adding different ratios of released drug to loaded drug through nanoparticles in the system, their release profile was examined. The results revealed that adding chitosan nanoparticles reduced burst release by 44% and increased the release time. In this system, the drug can be added to the polymer solution in different proportions of the free form and the drug-containing nanoparticle. Furthermore, in this system, it is possible to use the combination of different drugs in free form or loaded in nanoparticles to improve the treatment process in the system. The use of biodegradable polymers eliminates the need for surgery in the use of this medicinal system. Moreover, this system is biocompatible and non-toxic due to the non-use of organic solvent in the preparation of the system and the use of PEG 250 DME solvent.
SPC, Eurasian Chemical Communications (ECC), Jun 6, 2023
This study aimed to PEGylated cationic nano-niosomes formulation containing curcumin (CUR) for dr... more This study aimed to PEGylated cationic nano-niosomes formulation containing curcumin (CUR) for drug delivery to MCF-7 breast cancer cell lines and slow release of encapsulated CUR to reduce drug side effects on other healthy cells and increase drug effect on cancer cells. In this applied/in vitro study, PEGylated cationic nano-niosomes containing curcumin as herbal anticancer drug in MCF-7 cell line were prepared in laboratory through lipid phase mixing, phosphate buffer addition to a lipid thin film, and the production of nano-niosomes by sonication and dialysis process. Curcumin-containing niosomes were produced using the lipid phase by thin film fabrication method and reduced to a nanometer size by sonication. The average diameter (85.4 nm) of drug-carrying nano-niosomes was determined using a nano-sizer. Our results includes acquisition of technical knowledge of fabricating nano-niosomes containing a herbal bioactive ingredient as a nanosystem with the herbal medicine curcumin, proper loading of curcumin (with anticancer effect) at > 95% inside nano-niosomes with a size of < 100 nm to intensify the effectiveness of this medicine in cancer treatment, and preparation of PEGylated cationic nano-niosomes containing a body-compatible herbal bioactive substance with a slow release curve and good stability in terms of size and surface loading after 2 months of production. The produced curcumin-carrying liposomal nano-carrier has a slow-release curve and body biocompatibility that can be used in preparation of drug delivery systems containing similar hydrophobic drugs as an effective approach in treatment of various cancers, and agriculture, as well as in various pharmaceutical, medical, health, and environmental industries.